Showing 15 posts of 31 posts found.

Antion launch new technology for cancer and tumour treatments

March 18, 2021
Cancer, action, blood cancer, myeloma

Antion Biosciences has launched a new T-cell technology platform to help with the development of new curative therapies for diseases …


FDA fast-tracks GSK’s multiple myeloma drug after priority review

January 22, 2020
Research and Development BCMA, FDA, GSK, Phase 2 Trials, Phase Trials, multiple myeloma, myeloma

The FDA has fast tracked GlaxoSmithKline (GSK) antibody drug conjugate (ADC) belantamab mafodotin, for the treatment of patients with refractory …


NICE recommends Janssen’s Darzalex myeloma combo

March 12, 2019
Manufacturing and Production Janssen, NICE, Velcade, darzalex, myeloma

Britain’s cost effectiveness body NICE have recommended Janssen Pharmaceutical’s Darzalex in combination with Velcade and dexamethasone (DVd), for use within …


Amgen unveils double whammy of data for its investigational cancer immunotherapies at ASH 2018

December 5, 2018
Research and Development ASH 2018, Amgen, Cancer, acute myeloid leukaemia, myeloma, pharma

Amgen has presented the first clinical data at the American Society of Hematology (ASH) Annual Meeting 2018 for two investigational …

Empliciti pack shot

EMA fast-tracks BMS multiple myeloma drug

February 1, 2016
Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, EMA, Empliciti, myeloma

The EMA has recommended granting a marketing authorisation for Bristol Myers-Squibb and AbbVie’s immunotherapy Empliciti for the treatment of multiple myeloma. The …

Eric Low

Open access research partnership to ‘crowdsource’ new myeloma drugs

January 27, 2016
Research and Development Myeloma UK, Structural Genomics Consortium, collaboration, eric low, myeloma, partnership

Myeloma UK and the Structural Genomics Consortium (SGC) have entered into an open-access research partnership to find new drug targets …

Amgen image

FDA approves new Kyprolis combo for multiple myeloma

January 22, 2016
Medical Communications, Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma, myeloma

Amgen’s Kyprolis has been given another endorsement by the FDA as a multiple myeloma treatment – its second in six …


Takeda in myeloma research drive

January 14, 2016
Medical Communications, Research and Development Ninlaro, Phase II, Takeda, Takeda oncology, eric low, ixazomib, multiple myeloma, myeloma

Takeda is funding the research charity Myeloma UK to run a Phase II study of its multiple myeloma treatment Ninlaro, …

Takeda oncology

FDA approves Takeda’s Ninlaro for multiple myeloma

November 23, 2015
Manufacturing and Production, Research and Development Takeda, myeloma

The US Food and Drug Administration (FDA) has approved Takeda’s Ninlaro (ixazomib) for use in combination with lenalidomide and dexamethasone …


Novartis blood cancer drug Farydak receives EU approval

September 4, 2015
Sales and Marketing Cancer, European Commission, Farydak, Novartis, multiple myeloma, myeloma, panobinostat

The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …

Eric Low image

Myeloma charity body publishes its first trial results

June 9, 2015
Research and Development, Sales and Marketing ctn, eric low, muk one, myeloma

The Myeloma UK Clinical Trial Network (CTN) has published data from its first trial marking a major milestone for the …

Amgen image

Amgen files high earnings for Q1

April 22, 2015
Sales and Marketing AMG 334, Amgen, Corlanor, Kyprolis, Prolia, Q1, Xgeva, brodalumab, myeloma, osteoporosis

Amgen has boosted its first quarter profit by 51% due to surging drug sales and ongoing cuts that paved the …

FDA in Novartis cancer drug U-turn

February 24, 2015
Research and Development, Sales and Marketing Cancer, FDA, Farydak, Novartis, Revlimid, Velcade, myeloma

The FDA has overturned an earlier advisory committee recommendation and decided to approve Novartis’ blood cancer drug Farydak. In November …

Revlimid image

Celgene gets FDA licence extension for myeloma drug

February 19, 2015
Sales and Marketing Celgene, FDA, Revlimid, lenalidomide, myeloma

The FDA has given Celgene an extended licence for its multiple myeloma drug Revlimid (lenalidomid), to include people who are …

Celgene image

Celgene’s blood cancer pill too expensive for NHS

February 13, 2015
Sales and Marketing Celgene, NHS, NICE, Pomalidomide, imnovid, myeloma

NICE has decided not to recommend Celgene’s Imnovid for treating patients with multiple myeloma – a cancer that affects white …

Latest content